Multidisciplinary Management of Hepatocellular Carcinoma in Clinical Practice

Table 2

Activity and efficacy of sorafenib.

	Intent-to-treat Analysis
	Number	%
Enrolled patients	10	100
Evaluable patients	9	90
Objective response	2	22 (CI ± 29)
Partial response	2	22
Complete response	—	—
Stable disease	6	67
Progressive disease	1	11
Median progression-free survival, months	7
Range	2–34
Progression events	8	80
Median overall survival, months	9
Range	4–35+
Deaths	7	70